KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5551
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival ; day:14 ; month:3 ; year:2019 ; pages:1-5
Leukemia ; (14.3.2019), 1-5
- Creator
-
Vendramini, Elena
Bomben, Riccardo
Pozzo, Federico
Benedetti, Dania
Bittolo, Tamara
Rossi, Francesca Maria
Dal Bo, Michele
Rabe, Kari G.
Pozzato, Gabriele
Zaja, Francesco
Chiarenza, Annalisa
Di Raimondo, Francesco
Braggio, Esteban
Parikh, Sameer A.
Kay, Neil E.
Shanafelt, Tait D.
Del Poeta, Giovanni
Gattei, Valter
Zucchetto, Antonella
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-019-0444-6
- URN
-
urn:nbn:de:101:1-2019040718400250737571
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Vendramini, Elena
- Bomben, Riccardo
- Pozzo, Federico
- Benedetti, Dania
- Bittolo, Tamara
- Rossi, Francesca Maria
- Dal Bo, Michele
- Rabe, Kari G.
- Pozzato, Gabriele
- Zaja, Francesco
- Chiarenza, Annalisa
- Di Raimondo, Francesco
- Braggio, Esteban
- Parikh, Sameer A.
- Kay, Neil E.
- Shanafelt, Tait D.
- Del Poeta, Giovanni
- Gattei, Valter
- Zucchetto, Antonella
- SpringerLink (Online service)
Other Objects (12)
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen
Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Die kombinierte MEK- und BRAF-Inhibierung als neuer Therapieansatz beim NRAS-mutierten Melanom
NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas
NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Trisomy 21-driven metabolite alterations are linked to cellular injuries in Down syndrome
Cognitive impairments are independently associated with shorter survival in diffuse glioma patients
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen
Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Die kombinierte MEK- und BRAF-Inhibierung als neuer Therapieansatz beim NRAS-mutierten Melanom
NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas
NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Trisomy 21-driven metabolite alterations are linked to cellular injuries in Down syndrome
Cognitive impairments are independently associated with shorter survival in diffuse glioma patients
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
BRAF- und NRAS-Mutationen in Melanomen von Patienten mit Mehrfachmelanomen
Zirkulierende Tumor DNA erlaubt Therapiemonitoring in BRAF und NRAS mutiertem malignem Melanom
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Die kombinierte MEK- und BRAF-Inhibierung als neuer Therapieansatz beim NRAS-mutierten Melanom
NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas
NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Trisomy 21-driven metabolite alterations are linked to cellular injuries in Down syndrome
Cognitive impairments are independently associated with shorter survival in diffuse glioma patients
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas